Publications by authors named "Y Pastore"
A universal newborn screening program for sickle cell disease (uNS-SCD) was implemented in the province of Québec (Qc) in November 2013, close in time to the recommendation of early initiation of hydroxyurea (HU) therapy for children. This retrospective cohort study evaluated the impact of such a program on children first seen between January 2000 and December 2019. Cohorts pre-SCD-uNS in Qc (pre-QcNS) ( = 253) and post-QcNS ( = 157) for patients seen prior to or after Nov 2013 were compared.
View Article and Find Full Text PDFBackground: Red blood cell transfusion is an effective treatment for patients with sickle cell disease (SCD). Alloimmunization can occur after a single transfusion, limiting further usage of blood transfusion. It is recommended to match for the ABO, D, C, E, and K antigens to reduce risks of alloimmunization.
View Article and Find Full Text PDFBackground: Patients with sickle cell disease (SCD) are considered at higher risk of severe COVID-19 infection. However, morbidity and mortality rates are variable among countries. To date, there are no published reports that document outcomes of SCD patients with COVID-19 in Canada.
View Article and Find Full Text PDFArticle Synopsis
- A phase 3 clinical trial assessed the safety and effectiveness of rivipansel, an E-selectin antagonist, in 345 patients (adults and children) with vaso-occlusive crises (VOC) requiring hospitalization.
- The study found that rivipansel did not significantly improve the primary endpoint of time to readiness for discharge compared to placebo, although it did notably reduce soluble E-selectin levels in the treatment group.
- A post hoc analysis suggested that administering rivipansel early after VOC pain onset could significantly decrease the time to discharge and reduce opioid use, indicating that the timing of treatment may be key for better outcomes.